| Expression pattern: |
UP |
| Associated gene: |
PD-L1 |
| Associated microRNA: |
miR-1304-5p |
| Biological function: |
Promotes cisplatin resistance and immune escape in NSCLC cells; knockdown increases DDP sensitivity, enhances CD8+ T cell cytotoxicity, promotes tumor suppressor cytokine secretion, inhibits tumor-promoting cytokine secretion, and increases apoptosis under DDP treatment. |
| Molecular mechanism: |
circ_0068252 acts as a cytoplasmic ceRNA that adsorbs miR-1304-5p, thereby up-regulating PD-L1 expression and regulating DDP resistance and immune escape. |
| Biological pathway or process: |
chemoresistance (promotes); apoptosis (inhibits); immune regulation (inhibits); ceRNA regulation (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; MTT; Colony Formation Assay; ELISA; Western Blot; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; Bioinformatics Analysis; Cohort Study; Survival Analysis |
| Clinical significance: |
High circ_0068252 expression is correlated with poor prognosis and DDP resistance in NSCLC; circ_0068252 may be a potential diagnostic marker and therapeutic target for DDP-resistant NSCLC. |
| Description: |
hsa_circ_0068252/circ_0068252 is up-regulated in DDP-resistant NSCLC cells and tumor tissues, and high expression is associated with poor overall survival. It promotes cisplatin resistance and immune escape by acting as a cytoplasmic ceRNA that adsorbs miR-1304-5p to increase PD-L1 expression. Knockdown of circ_0068252 restores DDP sensitivity and enhances CD8+ T cell-mediated anti-tumor activity. |
| Confidence score: |
0.7628 |